Search
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigationalTriheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnFirst used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Piperazine was first introduced as an anthelmintic in 1953.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesEnlonstobart
go.drugbank.com/drugs/DB21890Investigational[A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.
Equine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.
Enzastaurin
go.drugbank.com/drugs/DB06486InvestigationalEnzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTegtociclib
go.drugbank.com/drugs/DB21635InvestigationalTegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid
Chlorambucil
go.drugbank.com/drugs/DB00291ApprovedInvestigationalA nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases.
Synonyms: 4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid, 4-(p-bis(β-chloroethyl)aminophenyl)butyric acidAT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. … GAA to the lysosome, where it can perform its normal function.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates